A bilirubin adsorbent with anticoagulant effect and its preparation method and application

Bilirubin adsorbent prepared by cross-linking sulfated polysaccharides with styrene-diethylenebenzene polymer, combined with sulfated soapyla polysaccharides, solve the problem of risk of coagulation and inflammatory infection in blood perfusion, and achieve efficient bilirubin Adsorption and anticoagulation properties improve treatment safety and economicality.

CN118513014BActive Publication Date: 2024-11-08TIANJIN SECOND PEOPLES HOSPITAL +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410979475.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-08
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

Existing bilirubin adsorbents have the risk of coagulation and inflammatory infection during blood perfusion, and long-term use of heparin as an anticoagulant may cause bleeding and multi-organ dysfunction, making it difficult to effectively reduce the dosage of heparin and improve treatment safety.

Method used

The bilirubin adsorbent prepared by chemical cross-linking of sulfated polysaccharides and styrene-diethylenebenzene polymers is prepared by suspension polymerization. Porous microspheres are combined with sulfated soapycapropene polysaccharides as anticoagulation modifications to improve adsorption effect and anticoagulation. Blood performance.

Benefits of technology

It significantly improves the adsorption effect of bilirubin and anticoagulant performance, reduces the use of heparin, reduces the risk of bleeding in patients, and provides a safer and more economical blood purification treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118513014B_ABST
    Figure CN118513014B_ABST
Patent Text Reader

Abstract

The invention discloses a bilirubin adsorbent with anticoagulant effect and its preparation method and application, belongs to the technical field of adsorbents for blood perfusion, and provides a bilirubin adsorbent with anticoagulant effect, wherein the bilirubin adsorbent is prepared by chemical crosslinking of sulfated polysaccharide and styrene-divinylbenzene polymer. The preparation method of the bilirubin adsorbent comprises the following steps: styrene-divinylbenzene polymer is soaked in an acidified solution, acidified, and vacuum dried to obtain a pretreated styrene-divinylbenzene polymer; mixed with an imine polymer solution, and subjected to an amination reaction to obtain an aminated styrene-divinylbenzene polymer; and sulfated polysaccharide is crosslinked in a constant temperature water bath under the action of a catalyst for 1 to 2 hours to obtain a bilirubin adsorbent. The bilirubin adsorbent of the present invention is applied to a blood perfusion system, and has good bilirubin adsorption effect and good anticoagulant performance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of adsorbents for blood perfusion, and in particular relates to a bilirubin adsorbent with anticoagulant effect, a preparation method and application thereof. Background Art

[0002] Hyperbilirubinemia is a disease characterized by an increase in the concentration of bilirubin in the blood, which in turn causes a series of damages to tissues and organs. Bilirubin is a type of bile pigment, orange-yellow in color. It is a metabolite of hemoglobin in the blood, is toxic, and can cause irreversible damage to the brain and nervous system. Hemoperfusion / plasmaperfusion (HP / plasmaperfusion, PP) is an effective method for removing bilirubin from the blood in clinical practice, which can alleviate the condition of patients with liver failure. The core of hemoperfusion is to use biomaterials as adsorbents to remove bilirubin from the blood. However, when the adsorbent interacts with blood as heterogeneous tissues, a plasma protein adsorption film is rapidly formed on the surface of the material. Protein adsorption on the surface of the material will activate the intrinsic and exogenous coagulation pathways, thereby forming thrombi and causing a coagulation waterfall; at the same time, inflammatory infection is also a common unsafe factor in the process of hemoperfusion. The anticoagulation method used in clinical use of hemoperfusion devices is to intravenously inject a certain amount of heparin into the patient to prevent the whole body blood from clotting. Although this method can ensure the smooth progress of blood purification treatment, long-term and large-scale use has the following three problems: it may cause uncontrollable bleeding; multiple organ dysfunction; it cannot prevent other reactions between the material and the blood, and even endanger life. Therefore, the development of hemoperfusion adsorption materials with strong anticoagulation ability is of great significance to reduce the amount of heparin used in the process of blood purification treatment and improve the safety of treatment.

[0003] At present, the main bilirubin adsorbents are activated carbon and synthetic resins. Activated carbon has a poor adsorption effect on bilirubin. At the same time, it is difficult to modify activated carbon and it is difficult to have more functions. Synthetic resins have the characteristics of high adsorption capacity, easy structural modification, short adsorption equilibrium time, good blood compatibility and stability, and are more suitable for the treatment of hyperbilirubinemia. The adsorption rate of synthetic resin bilirubin adsorbents with relatively mature clinical applications is mostly between 15% and 30%, and there is a risk of coagulation and infection when used in vitro.

[0004] The main technical means of constructing anticoagulant surfaces is to graft macromolecules with high hydrodynamic volume or substances with anticoagulant function, such as heparin and protein C system, onto the surface of polymer materials. Whether it is grafted macromolecules or natural anticoagulants, the methods have certain limitations. Grafted macromolecules affect the biocompatibility of the material itself to a certain extent; and surface heparinization is prone to cause bleeding risks and is costly. Therefore, it is particularly important to explore safer anticoagulant materials to graft and modify adsorption materials to improve their anticoagulant effects. How to improve the anticoagulant activity and anti-inflammatory activity of hemoperfusion bilirubin adsorbents, reduce the use of anticoagulants such as heparin, and reduce the risk of bleeding in patients are urgent issues to be solved in clinical hemoperfusion therapy. Summary of the invention

[0005] In order to solve the above technical problems, the present invention proposes a bilirubin adsorbent with anticoagulant effect, a preparation method and application thereof. The bilirubin adsorbent of the present invention is prepared by chemically cross-linking sulfated polysaccharide and styrene-divinylbenzene polymer, and is applied to a blood perfusion system. It has good bilirubin adsorption effect, good anticoagulant performance and broad application prospects.

[0006] To achieve the above object, the present invention provides a bilirubin adsorbent with anticoagulant effect, wherein the bilirubin adsorbent is prepared by chemically cross-linking sulfated polysaccharide and styrene-divinylbenzene polymer.

[0007] Preferably, the mass ratio of the sulfated polysaccharide to the styrene-divinylbenzene polymer in the bilirubin adsorbent is (5-15):(85-95); the sulfated polysaccharide is sulfated saponin polysaccharide.

[0008] The present invention also provides a method for preparing the bilirubin adsorbent, comprising the following steps:

[0009] (1) immersing the styrene-divinylbenzene polymer in an acidified solution, acidifying it, and vacuum drying it to obtain a pretreated styrene-divinylbenzene polymer;

[0010] (2) the pretreated styrene-divinylbenzene polymer obtained in step (1) is mixed with the imine polymer solution and subjected to an amination reaction to obtain an aminated styrene-divinylbenzene polymer;

[0011] (3) The aminated styrene-divinylbenzene polymer obtained in step (2) and the sulfated polysaccharide are cross-linked in a constant temperature water bath for 1 to 2 hours under the action of a catalyst to obtain a bilirubin adsorbent.

[0012] Preferably, the acidified solution in step (1) is an acid solution with a mass fraction of 25-65%; the time of the acidification treatment in step (1) is 2-10 min; the mass fraction of the imine polymer solution in step (2) is 0.03-0.05%, and the imine polymer solution is a polypropylene imine solution; the ratio of the pretreated styrene-divinylbenzene polymer and the imine polymer solution in step (2) is 100-150 mL: 150-300 mL.

[0013] Preferably, the catalyst in step (3) is one or more of KCN, NaSH and CH3BNNa; the amount of the catalyst in step (3) is 0.05-0.15% of the total mass of the reaction system; the temperature of the constant temperature water bath cross-linking in step (3) is 35-45°C.

[0014] Preferably, the sulfated Gleditsia sinensis polysaccharide is prepared according to the following steps:

[0015] Gleditsia sinensis is crushed, and water is used as an extracting liquid to extract Gleditsia sinensis polysaccharide; the Gleditsia sinensis polysaccharide is mixed with a sulfating agent, reacted for 3 to 5 hours, and dialyzed to obtain a precipitate, wherein the precipitate is sulfated Gleditsia sinensis polysaccharide.

[0016] Further preferably, the ratio of the saponin polysaccharide to the sulfation reagent is 1 g:6 mL; and the reaction is carried out in an ice bath.

[0017] Preferably, the styrene-divinylbenzene polymer is prepared according to the following steps:

[0018] Styrene and divinylbenzene are mixed, and an initiator and a porogen are added to prepare an organic phase; the organic phase is homogeneously dispersed with an aqueous solution of hydroxyethyl cellulose to obtain a mixed solution, and the mixed solution is prepared by a suspension polymerization method to obtain a styrene-divinylbenzene polymer.

[0019] Further preferably, the initiator is azobisisobutyronitrile; the porogen is prepared by mixing toluene, cyclohexanol and n-heptane in a volume ratio of 1:1:0.5; the homogenization time is 2 to 5 minutes, and the homogenization speed is 12000 to 15000 kr / min.

[0020] The present invention also provides the use of the bilirubin adsorbent or the bilirubin adsorbent obtained by the preparation method in a blood perfusion system and / or a plasma perfusion system.

[0021] Compared with the prior art, the present invention has the following advantages and technical effects:

[0022] The bilirubin adsorbent of the present invention is prepared by chemical crosslinking of a sulfated polysaccharide modifier and a styrene-divinylbenzene polymer. The styrene-divinylbenzene polymer uses styrene and divinylbenzene as monomers, and an initiator and a porogen are added to the system, and is prepared by a suspension polymerization method. The present invention adds a homogeneous dispersion treatment preparation step, and the improved suspension polymerization method successfully prepares monodisperse porous microspheres with uniform particle size, and the particle size range is mostly distributed between 150 and 300 μm, and the acquisition rate is higher than the traditional preparation method. The present invention uses a new porous polymer adsorption resin styrene-divinylbenzene polymer modified with sulfated saponin polysaccharide as an adsorption material, which is applied to a blood perfusion system. Compared with traditional adsorption materials, the present invention has good bilirubin adsorption effect, good anticoagulant performance and broad application prospects.

[0023] The details are as follows: 1) The present invention uses sulfated saponin polysaccharides as anticoagulant modifiers. Saponin contains about 80% polysaccharides, which are mainly composed of monosaccharides such as galactose, mannose, glucose and arabinose. The present invention proves that sulfated saponin polysaccharides have anticoagulant function and good biocompatibility. 2) The anticoagulant effect of sulfated saponin polysaccharides reduces the risk of bleeding compared to heparin, and is safe, effective and inexpensive. 3) In addition to having a high bilirubin adsorption effect, the bilirubin adsorbent prepared by the present invention also has anticoagulant properties due to the modification of sulfated saponin polysaccharides. 4) The raw materials of the bilirubin adsorbent described in the present invention are new porous polymer adsorption resin styrene-divinylbenzene polymer and sulfated saponin polysaccharides. The raw materials are easy to obtain and the preparation process is not complicated. Therefore, both therapeutic benefits and economic benefits are taken into account, and a safer and more effective treatment plan can be provided, the safety of in vitro perfusion can be improved, and the economic burden on patients can be reduced. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 The complete infrared spectra of the bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1;

[0026] Figure 2 Partial infrared spectra of the bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1;

[0027] Figure 3 This is the electron microscope scanning result of the bilirubin adsorbent prepared in Example 1;

[0028] Figure 4 The elemental analysis results of the styrene-divinylbenzene polymer prepared in Example 1;

[0029] Figure 5 The elemental analysis results of the bilirubin adsorbent prepared in Example 1;

[0030] Figure 6 This is a cross-sectional electron micrograph of the bilirubin adsorbent prepared in Example 1;

[0031] Figure 7 is the structural diagram of albumin, where 136.95 angstroms represents the distance between the two most distant atoms, and 85 angstroms represents the distance between the two most distant atoms;

[0032] Figure 8 This is the structural diagram of bilirubin, where 24.4 angstroms represents the distance between the two farthest atoms;

[0033] Fig. 9 This is a graph showing the in vitro coagulation effect of the bilirubin adsorbent prepared in Example 1;

[0034] Fig.10 This is an electron scanning micrograph of the styrene-divinylbenzene polymer prepared in Example 1;

[0035] Fig.11 This is an electron scanning micrograph of the bilirubin adsorbent prepared in Example 1;

[0036] Fig.12 This is the result diagram of the fluorescence value measurement of the adsorption solution;

[0037] Fig.13 This is a statistical chart of changes in thrombus weight;

[0038] Fig.14 This is an electron microscope scanning image of the surface of the bilirubin adsorbent prepared in Example 1;

[0039] Fig.15 This is a surface electron microscope scanning image of the styrene-divinylbenzene polymer prepared in Example 1;

[0040] Fig.16 This is the elemental analysis diagram of the styrene-divinylbenzene polymer obtained in Example 1 after adsorption;

[0041] Fig.17 This is the result of the hemolysis test;

[0042] Fig.18 This is the staining result of cells in the control group;

[0043] Fig.19 This is the result of cell staining in the GLU-ERM-0100 experimental group;

[0044] Fig. 20 It is the result of cell inhibition rate determination;

[0045] Fig.21 This is the proliferation status of macrophages in the GLU-ERM-0100 experimental group;

[0046] Fig. 22 This is the macrophage proliferation status of the lipopolysaccharide positive group;

[0047] Fig.23 It is a statistical chart of interleukin-6 secretion status;

[0048] Fig.24 This is a statistical chart of tumor necrosis factor secretion;

[0049] Fig.25 The effect of different concentrations of NaCl on the adsorption efficiency of bilirubin;

[0050] Fig.26 The effect of different concentrations of bovine serum albumin on the adsorption efficiency of bilirubin;

[0051] Fig. 27 This is a statistical chart of bilirubin clearance efficiency;

[0052] Fig.28 It is a statistical chart of the clearance efficiency of total bilirubin, direct bilirubin and indirect bilirubin. DETAILED DESCRIPTION

[0053] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0054] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0055] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0056] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0057] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0058] Example 1

[0059] Weigh 290g of sapodilla, crush it through a 60-mesh sieve to obtain sapodilla powder; use water as the extracting solution, take 5500mL of water and mix it with sapodilla powder, adjust the pH to 10 with 1mol / L NaOH solution, extract polysaccharides, soak for 24 hours after adjusting the pH, stir evenly and leave at room temperature overnight; then control the temperature between 40~45℃ and heat and stir for 5 hours, filter and take the residue as the sapodilla polysaccharide extract; heat and pressurize the sapodilla polysaccharide extract (pressure is 0.04MPa, temperature is 75℃) to concentrate to 2900mL, mix it with 3 times the volume mass fraction of 96% ethanol aqueous solution, stir evenly, let it stand, take the precipitate, and dry it at 40℃ for 60 hours to obtain sapodilla polysaccharide.

[0060] Under ice bath conditions, a 95% ethanol aqueous solution was slowly dripped into 250 mL of 98% concentrated sulfuric acid, and stirred for 8 hours to prepare a sulfation reagent; the saponin polysaccharide was freeze-dried at -90 ° C for 24 hours, and the freeze-dried saponin polysaccharide was mixed with the sulfation reagent in a ratio of 1 g: 6 mL, reacted under ice bath conditions for 4 hours, and a 1 mol / L NaOH solution was used to adjust the pH to 7.2 to obtain a light yellow solution; the light yellow solution was dialyzed for 24 hours using a 7000Da dialysis bag, during which deionized water was replaced 3 times, and then poured into 3 times the volume of a 95% ethanol aqueous solution, allowed to stand for 24 hours, and the precipitate was taken, and ventilated and dried at 40 ° C for 18 hours to obtain sulfated saponin polysaccharide. The sulfated saponin polysaccharide was dissolved in pure water to prepare a sulfated saponin polysaccharide solution with a concentration of 1.5 g / L.

[0061] Take 100 mL of styrene, 25 mL of divinylbenzene, 0.1 g of azobisisobutyronitrile, 0.5 mL of 0.1% methylene blue aqueous solution, 15 mL of 5% sodium chloride aqueous solution and 15 mL of porogen (prepared by mixing toluene, cyclohexanol and n-heptane in a volume ratio of 1:1:0.5), mix them, and stir them with a magnetic stir at 450 r / min for 25 min to prepare an organic phase.

[0062] The organic phase and the aqueous solution of 5% by mass of hydroxyethyl cellulose (aqueous phase) are in a volume ratio of 1:3, and the organic phase is slowly dispersed into the aqueous phase, homogenized at 13500 kr / min for 3 min, and then prepared by suspension polymerization, stirred at 70°C for 24 h, and the stirring speed is 400 r / min, and the precipitate obtained by the reaction is retained; the precipitate is washed with distilled water, acetone, and ethanol for 3 times each, extracted with toluene for 16 h, washed alternately with ethanol and distilled water for 3 times each, and finally vacuum dried at 45°C and -0.8 mPa vacuum for 24 h to obtain styrene-divinylbenzene polymer.

[0063] 55 mL of 98% concentrated sulfuric acid, 200 mL of water and 0.4 g of KMnO4 were mixed to prepare an acid solution, and the styrene-divinylbenzene polymer was immersed in the acidified solution, acidified for 6 minutes, and rinsed with distilled water to obtain a pretreated styrene-divinylbenzene polymer; the pretreated styrene-divinylbenzene polymer was mixed with 0.04% imine polymer solution in a ratio of 150 mL:300 mL to carry out an amination reaction. After terminating the reaction, the aminated styrene-divinylbenzene polymer was taken out and rinsed with distilled water for 4 times.

[0064] The aminated styrene-divinylbenzene polymer and the sulfated saponin polysaccharide solution were mixed in a volume ratio of 80%:20%, KCN was used as a catalyst, the amount of KCN was 0.1% of the total mass of the reaction system, and cross-linking was carried out in a constant temperature water bath at 40°C for 1.5h to obtain a bilirubin adsorbent.

[0065] Example 2

[0066] Weigh 290g of sapodilla, crush it through a 60-mesh sieve to obtain sapodilla powder; use water as the extracting solution, take 5500mL of water and mix it with sapodilla powder, adjust the pH to 10 with 1mol / L NaOH solution, extract polysaccharides, soak for 24h after adjusting the pH, stir evenly and leave at room temperature overnight; then control the temperature between 35~43℃ and heat and stir for 4h, filter and take the residue as the sapodilla polysaccharide extract; heat and pressurize the sapodilla polysaccharide extract (pressure is 0.04MPa, temperature is 70℃) to concentrate to 2900mL, mix it with 3 times the volume mass fraction of 96% ethanol aqueous solution, stir evenly, let it stand, take the precipitate, and dry it at 40℃ for 48h to obtain sapodilla polysaccharide.

[0067] Under ice bath conditions, a 95% ethanol aqueous solution was slowly dripped into 250 mL of 98% concentrated sulfuric acid, and the reaction was stirred for 8 hours to prepare a sulfation reagent; the saponin polysaccharide was freeze-dried at -80°C for 24 hours, and the freeze-dried saponin polysaccharide was mixed with the sulfation reagent at a mass ratio of 200:1, reacted under ice bath conditions for 4 hours, and a 1 mol / L NaOH solution was used to adjust the pH to 7.2 to obtain a light yellow solution; the light yellow solution was dialyzed for 24 hours using a 7000Da dialysis bag, during which deionized water was replaced 3 times, and then poured into 3 times the volume of a 95% ethanol aqueous solution, allowed to stand for 24 hours, and the precipitate was taken, and dried at 40°C for 12 hours to obtain sulfated saponin polysaccharide. The sulfated saponin polysaccharide was dissolved in pure water to prepare a sulfated saponin polysaccharide solution with a concentration of 0.8 g / L.

[0068] Take 100 mL of styrene, 25 mL of divinylbenzene, 0.1 g of azobisisobutyronitrile, 0.5 mL of 0.1% methylene blue aqueous solution, 15 mL of 5% sodium chloride aqueous solution and 15 mL of porogen (prepared by mixing toluene, cyclohexanol and n-heptane in a volume ratio of 1:1:0.5), mix them, and stir them magnetically at 400 r / min for 30 min to prepare an organic phase.

[0069] The organic phase and the aqueous solution of 5% by mass of hydroxyethyl cellulose (aqueous phase) are in a volume ratio of 1:3, and the organic phase is slowly dispersed into the aqueous phase, homogenized at 12000kr / min for 5 minutes, and then prepared by suspension polymerization, stirred at 70°C for 24 hours, and the stirring speed is 400r / min, and the precipitate obtained by the reaction is retained; the precipitate is washed with distilled water, acetone, and ethanol for 3 times each, extracted with toluene for 8 hours, and washed alternately with ethanol and distilled water for 3 times each, and finally vacuum dried at 40°C and -0.8mPa vacuum for 24 hours to obtain styrene-divinylbenzene polymer.

[0070] 30 mL of 98% concentrated sulfuric acid, 154 mL of water and 0.3 g of KMnO4 were mixed to prepare an acid solution, and the styrene-divinylbenzene polymer was immersed in the acidified solution, acidified for 10 min, and rinsed with distilled water to obtain a pretreated styrene-divinylbenzene polymer; the pretreated styrene-divinylbenzene polymer was mixed with 0.03% imine polymer solution in a ratio of 100 mL:300 mL to carry out an amination reaction. After terminating the reaction, the aminated styrene-divinylbenzene polymer was taken out and rinsed with distilled water 3 times.

[0071] The aminated styrene-divinylbenzene polymer and the sulfated saponin polysaccharide solution were mixed in a volume ratio of 90%:10%, and NaSH was used as a catalyst. The amount of NaSH was 0.05% of the total mass of the reaction system. The mixture was cross-linked in a constant temperature water bath at 35°C for 2h to obtain a bilirubin adsorbent.

[0072] Example 3

[0073] Weigh 290g of sapodilla, crush it through a 60-mesh sieve to obtain sapodilla powder; use water as the extracting solution, take 5500mL of water and mix it with sapodilla powder, adjust the pH to 10 with 1mol / L NaOH solution, extract polysaccharides, soak for 24h after adjusting the pH, stir evenly and leave at room temperature overnight; then control the temperature between 46~50℃ and heat and stir for 6h, filter and take the residue as the sapodilla polysaccharide extract; heat and pressurize the sapodilla polysaccharide extract (pressure is 0.04MPa, temperature is 80℃) to concentrate to 2900mL, mix it with 3 times the volume mass fraction of 96% ethanol aqueous solution, stir evenly, let it stand, take the precipitate, and dry it at 40℃ for 72h to obtain sapodilla polysaccharide.

[0074] Under ice bath conditions, a 95% ethanol aqueous solution was slowly dripped into 250 mL of 98% concentrated sulfuric acid, and the mixture was stirred for 8 h to prepare a sulfation reagent; the saponin polysaccharide was freeze-dried at -100 °C for 24 h, and the freeze-dried saponin polysaccharide was mixed with the sulfation reagent at a mass ratio of 250:1, and reacted under ice bath conditions for 4 h. A 1 mol / L NaOH solution was used to adjust the pH to 7.2 to obtain a light yellow solution; the light yellow solution was dialyzed for 24 h using a 7000Da dialysis bag, during which deionized water was replaced 3 times, and then poured into 3 times the volume of a 95% ethanol aqueous solution, and allowed to stand for 24 h. The precipitate was taken and dried at 40 °C for 24 h to obtain sulfated saponin polysaccharide. The sulfated saponin polysaccharide was dissolved in pure water to prepare a sulfated saponin polysaccharide solution with a concentration of 2.1 g / L.

[0075] Take 100 mL of styrene, 25 mL of divinylbenzene, 0.1 g of azobisisobutyronitrile, 0.5 mL of 0.1% methylene blue aqueous solution, 15 mL of 5% sodium chloride aqueous solution and 15 mL of porogen (prepared by mixing toluene, cyclohexanol and n-heptane in a volume ratio of 1:1:0.5), mix them, and stir them magnetically at 500 r / min for 20 min to prepare an organic phase.

[0076] The organic phase and the aqueous solution of 5% by mass of hydroxyethyl cellulose (aqueous phase) are in a volume ratio of 1:3, and the organic phase is slowly dispersed into the aqueous phase, homogenized at 15000 kr / min for 2 min, and then prepared by suspension polymerization, stirred at 70°C for 24 h, and the stirring speed is 400 r / min, and the precipitate obtained by the reaction is retained; the precipitate is washed with distilled water, acetone, and ethanol for 3 times each, extracted with toluene for 24 h, washed alternately with ethanol and distilled water for 3 times each, and finally vacuum dried at 50°C and -0.8 mPa vacuum for 24 h to obtain styrene-divinylbenzene polymer.

[0077] 70 mL of 98% concentrated sulfuric acid, 252 mL of water and 0.5 g of KMnO4 were mixed to prepare an acid solution, and the styrene-divinylbenzene polymer was immersed in the acidified solution, acidified for 2 minutes, and rinsed with distilled water to obtain a pretreated styrene-divinylbenzene polymer; the pretreated styrene-divinylbenzene polymer was mixed with a 0.05% imine polymer solution in a ratio of 150 mL:200 mL to carry out an amination reaction. After terminating the reaction, the aminated styrene-divinylbenzene polymer was taken out and rinsed with distilled water 5 times.

[0078] The aminated styrene-divinylbenzene polymer and the sulfated saponin polysaccharide solution were mixed in a volume ratio of 70%:30%, CH3BNNa was used as a catalyst, the amount of CH3BNNa was 0.15% of the total mass of the reaction system, and the mixture was cross-linked in a constant temperature water bath at 45°C for 1 hour to obtain a bilirubin adsorbent.

[0079] Experimental example

[0080] 1. Product characterization of the styrene-divinylbenzene polymer (ERM-0100) prepared in Example 1 and the bilirubin adsorbent (GLU-ERM-0100) prepared in Example 1:

[0081] (1) Infrared spectroscopic analysis of the bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1.

[0082] 1 mg of the bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1 were added to 100 mg of KBr and ground until mixed evenly, and then tabletted. The tablets were placed in a TENSOR27 Fourier transform infrared spectrometer to scan the bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1.

[0083] (2) Scanning electron microscopy analysis of the bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1.

[0084] Scanning electron microscope (SEM) can directly observe the surface morphology of the bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1. Since the bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1 are not conductive, they need to be plated with gold in advance. The dried bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1 are evenly coated on a glass slide, and the bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1 are subjected to gold spraying by an ion sputtering device. The surface morphology and particle size distribution of the bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1 are obtained by a HITACHI S-510 scanning electron microscope (SEM).

[0085] The results are as follows Figure 1 and Figure 2 As shown, the infrared spectra of the bilirubin adsorbent prepared in Example 1 and the styrene-divinylbenzene polymer prepared in Example 1 are at 1100 cm -1 、1630cm -1 and 789cm -1 There are obvious differences, among which 1100cm -1 and 789cm -1 The SO bonds and CS bonds at the bottom indicate that the sulfated polysaccharide has been bound to the resin.

[0086] The scanning electron microscopy results showed that the bilirubin adsorbent resin prepared in Example 1 was spherical and had a smooth surface (e.g. Figure 3 As shown in FIG. 1 ), the elemental analysis results show that compared with the styrene-divinylbenzene polymer prepared in Example 1 (as shown in FIG. Figure 4 As shown), the bilirubin adsorbent prepared in Example 1 (as Figure 5 The addition of sulfur and nitrogen also indicates that the resin is modified with sulfated polysaccharides. Figure 6 Shown is a cross-sectional electron microscope image of the bilirubin adsorbent prepared in Example 1.

[0087] 2. Biosafety Testing:

[0088] Determination of hemolysis test, cytotoxicity test, inflammatory response test and factor expression level of the styrene-divinylbenzene polymer (ERM-0100) prepared in Example 1 and the bilirubin adsorbent (GLU-ERM-0100) prepared in Example 1

[0089] (1) Hemolysis test:

[0090] First, 5 mL of whole blood was added to 10 mL of PBS solution without calcium and magnesium, and then centrifuged at 2000 r / min for 10 min to separate red blood cells (RBCs) from plasma. The centrifugation process was repeated 5 times. For the hemolysis test, 1 mL of the diluted red blood cell suspension (approximately 10 8 Cells / mL) were added to resin microspheres (styrene-divinylbenzene polymer (ERM-0100) prepared in Example 1 or bilirubin adsorbent (GLU-ERM-0100) prepared in Example 1), and a certain amount of microspheres were first soaked in PBS overnight and then incubated at 37°C for 3h. PBS was selected as a negative control and deionized water as a positive control. The suspension was then centrifuged at 8000r / min for 3min, and the absorbance of hemoglobin released from the suspension was measured at 540nm using an ultraviolet-visible spectrometer (UV-1750, Shimadzu Co., Ltd., Japan), and the hemolysis rate of the microspheres was calculated according to the following formula:

[0091] Hemolysis rate (%) = (As-An) / (Ap-An) × 100%

[0092] Where As is the absorbance of the suspension, Ap and An are the absorbance of the positive control and negative control, respectively.

[0093] (2) Cytotoxicity assay:

[0094] A. L929 cells were adjusted to a cell density of 5 × 10 4 / mL, plated in a 96-well cell culture plate, 100 μL / well, and continued conventional culture for 24 hours;

[0095] B. When the cell confluence reaches more than 70%, discard the supernatant and divide the cells into the following 4 groups, with 6 wells in each group:

[0096] a. Control group: cells cultured with growth medium;

[0097] b. Extract group 1: The culture medium containing 20% ​​FBS and extract 1 (PBS extract of styrene-divinylbenzene polymer (ERM-0100) prepared in Example 1) were mixed in a ratio of 1:1 and then the cells were cultured (the extract was finally diluted 2 times);

[0098] c. Extract group 2: The culture medium containing 20% ​​FBS and extract 2 (PBS extract of the bilirubin adsorbent (GLU-ERM-0100) prepared in Example 1) were mixed in a ratio of 1:1 and then the cells were cultured (the extract was finally diluted 2 times);

[0099] dSolvent group: growth medium without cells.

[0100] C. After 24 hours at 37°C and 5% CO2, add 10 μL of CCK8 solution to each well and react at 37°C for 2 hours;

[0101] D. Read the OD value at 450nm and calculate the cell proliferation inhibition rate:

[0102] Cell inhibition rate = [(OD value of control group - OD value of experimental group) / (OD value of control group - OD value of solvent group)] × 100%

[0103] (3) Cell life and death staining:

[0104] A. L929 cells were adjusted to a cell density of 5 × 10 4 / mL, spread in a 24-well cell culture plate, 500μL / well, and continue conventional culture for 24h;

[0105] B. When the cell confluence reaches more than 70%, discard the supernatant and divide the cells into the following 3 groups, with 3 replicates in each group:

[0106] a. Control group: cells cultured with growth medium;

[0107] b. Extract group: The culture medium containing 20% ​​FBS was mixed with extract 1 or extract 2 at a volume ratio of 1:1 and then the cells were cultured (the extract was finally diluted 2 times).

[0108] C. After 24 hours at 37°C and 5% CO2, carefully remove the culture medium of the adherent cells and add 500 μL PBS to each well to wash the cells twice;

[0109] D. Aspirate and discard PBS, add 200 μL of assay buffer, 2 μL of calcein (green dye), and 2 μL of propidium iodide (red dye) to each well, and incubate at 37°C for 30 min.

[0110] E. After incubation, observe the staining effect under a fluorescence microscope (green fluorescence, Ex / Em=494nm / 517nm; red fluorescence, Ex / Em=535nm / 617nm).

[0111] (4) Cytokine detection:

[0112] A. Move all reagents to room temperature for 30 minutes for standby use;

[0113] B. Standard dilution: For cell supernatant, the concentrations of each standard are: IL6: 120, 80, 40, 20, 10, 0 pg / mL; TNF-α: 120, 80, 40, 20, 10, 0 pg / mL;

[0114] C. Sample addition: Add 100 μL of standard to each well of the standard sample and gently shake to mix; add 4-fold diluted cell supernatant to the sample well (the dilution buffer is the sample diluent).

[0115] D. Add 100 μL of biotin-labeled antibody working solution to each well, cover with plate sticker, and incubate at 37°C for 2 h;

[0116] E. Discard the liquid in the wells, spin dry, and wash the plate 3 times. Soak for 2 minutes each time, 350μL / well, spin dry;

[0117] F. Add 100 μL of horseradish peroxidase-labeled avidin working solution to each well, cover with a new plate sticker, and incubate at 37°C for 45 min;

[0118] G. Discard the liquid in the wells, spin dry, and wash the plate 5 times. Soak for 2 minutes each time, 350uL / well, spin dry;

[0119] H. Add 90 μL of substrate solution to each well in sequence and color develop at 37°C in the dark for 15 min;

[0120] I. Add 50 μL of stop solution to each well to terminate the reaction;

[0121] J. Within 5 minutes after the reaction is terminated, use a microplate reader to measure the optical density (OD value) of each well in sequence at a wavelength of 450 nm;

[0122] K. Use SoftMax software to draw a standard curve based on the standard concentration and OD value, and use the software to automatically calculate the concentration of the sample to be tested.

[0123] The results are as follows Fig.17 As shown, compared with the positive control group, the experimental group and the negative control group were the same and did not cause hemolytic reaction; Fig.18 , 19 As shown in Figure 20, the cell staining results and cell inhibition rate results indicate that the resin material has good cell safety; Fig.21 and 22 As shown, compared with the positive group (such as Fig. 22 Compared with the experimental group (as shown Fig.21 ) does not induce abnormal proliferation of macrophages, nor does it mediate the secretion of interleukin-6 and tumor necrosis factor (as shown in Fig.23 and 24 ), indicating that the resin material does not cause inflammatory response.

[0124] 3. Anticoagulation test:

[0125] In order to explore the anticoagulant effect of Gleditsia sinensis polysaccharides after sulfation modification and the effect of different concentrations of sulfated Gleditsia sinensis polysaccharides on the anticoagulant effect, the in vitro anticoagulant activity experiment of Gleditsia sinensis polysaccharides was selected.

[0126] The plasma obtained from healthy volunteers and 3.8% sodium citrate were mixed at a volume ratio of 9:1, centrifuged at 4000r / min for 20min, and the supernatant was collected to obtain the plasma to be tested, which was placed in a vacuum blood collection tube and stored at 4°C. The sulfated saponin polysaccharide prepared in Example 1 was dissolved in physiological saline to prepare sulfated saponin polysaccharide solution samples with mass concentrations of 1mg / mL, 2mg / mL, 4mg / mL, 8mg / mL, and 10mg / mL; then the plasma to be tested and the sulfated saponin polysaccharide solution samples of different concentrations were mixed at a volume ratio of 4:1 to serve as the sample solution to be tested; physiological saline was used as a negative control, and sodium heparin was used as a positive control, and then an in vitro anticoagulant activity study was performed.

[0127] A. APTT (activated partial thromboplastin time) determination: take 50 μL of the sample solution to be tested, preheat it at 37℃ for 3 minutes, then add an equal volume of APTT reagent, keep warm for 5 minutes, then add 50 μL of CaCl2 solution preheated at 37℃, and record the coagulation time with an instrument.

[0128] B. Determination of PT (prothrombin time): Take 50 μL of the sample solution to be tested, preheat it at 37℃ for 3 minutes, then add 50 μL of PT reagent, and record the coagulation time with an instrument.

[0129] C. Determination of TT (thrombin time): Take 50 μL of the sample solution to be tested, preheat it at 37℃ for 3 minutes, then add 50 μL of TT reagent, and record the coagulation time with an instrument.

[0130] 4. Surface protein adsorption experiment:

[0131] Fluorescein-labeled bovine serum albumin (FITC-BSA) was diluted to 1 mg / mL with PBS solution. Then, the styrene-divinylbenzene polymer prepared in Example 1 and the bilirubin adsorbent prepared in Example 1 were added to the diluted FITC-BSA solution. Next, the solution was filtered to test the fluorescence intensity of the adsorbed solution; and the fluorescence imaging of the surfaces of different materials was observed using a fluorescence microscope.

[0132] 5. Thrombus determination experiment:

[0133] The styrene-divinylbenzene polymer (ERM-0100) sample prepared in Example 1 or the bilirubin adsorbent (GLU-ERM-0100) sample prepared in Example 1 was immersed in platelet-rich plasma (PRP), which was separated from fresh human whole blood by centrifugation. All samples were incubated with PRP at 37°C for 1 hour, washed with PBS, and then fixed for 12 hours. After drying, the materials were weighed and compared with the weight before the experiment; then, after dehydration, dealcoholization and gold spraying, the morphology of platelets adhered to the uncoated and coated resins was observed using a scanning electron microscope (SEM). At the same time, the element types were measured by the element analyzer vario EL Cube.

[0134] like Fig. 9 Shown are the statistical results of the in vitro coagulation effect of the bilirubin adsorbent prepared in Example 1.

[0135] The results are as follows Fig.10 , 11 As shown, the obtained styrene-divinylbenzene polymer (such as Fig.10 Compared with the bilirubin adsorbent prepared in Example 1, only a small amount of fluorescent protein is attached to the surface. At the same time, the fluorescence values ​​of the adsorption solutions of the two are measured, as shown in FIG. Fig.12 As shown, since the protein is adsorbed on the resin, the fluorescence value of the styrene-divinylbenzene polymer adsorption solution prepared in Example 1 is significantly lower than that of the bilirubin adsorbent adsorption solution prepared in Example 1, which is consistent with the fluorescence imaging result.

[0136] like Fig.13 As shown, as the incubation time increases, the weight of the bilirubin adsorbent prepared in Example 1 is almost unchanged. In sharp contrast, the weight of the styrene-divinylbenzene polymer prepared in Example 1 increases with time. The results of scanning electron microscopy are consistent with this. After incubation, the bilirubin adsorbent prepared in Example 1 (such as Fig.14 The surface of the styrene-divinylbenzene polymer (as shown in Fig.15 The surface of the Fig.16 As shown in Figure 1, the styrene-divinylbenzene polymer prepared in Example 1 has iron and sulfur elements on its surface, which may be the result of the attachment of hemoglobin or other proteins. The above results show that the bilirubin adsorbent prepared in Example 1 has good anti-thrombotic properties.

[0137] The results of the determination of the effects of different concentrations of sulfated saponin polysaccharide solutions on APTT, PT and TT showed that compared with normal saline, sulfated saponin polysaccharide had a weaker effect on APTT. With the increase of its mass concentration, the increase in APTT time was not very large, indicating that sulfated saponin polysaccharide did not play an anticoagulant role by participating in the intrinsic coagulation pathway; in the mass concentration range of 5-10 mg / mL, the effect of sulfated saponin polysaccharide on PT and TT reached a significant level (P < 0.05). When the concentration of sulfated saponin polysaccharide reached 6 mg / mL, compared with normal saline, sulfated saponin polysaccharide could significantly prolong the time of PT and TT by 43.54% and 35.27%, respectively. It shows that sulfated saponin polysaccharide has good anticoagulant activity, and it can play an anticoagulant role by participating in the extrinsic coagulation pathway or the common pathway.

[0138] 6. Bilirubin adsorption capacity test:

[0139] (1) 25 mL of the styrene-divinylbenzene polymer prepared in Example 1 and 25 mL of the bilirubin adsorbent prepared in Example 1 were respectively placed in a self-made perfusion tank, sterilized at 132°C and 0.21 MPa high pressure steam for 15 min for later use, and the container containing 250 mL of plasma was placed in a 37°C constant temperature water bath, and protected from light through the perfusion pipeline and peristaltic pump. The peristaltic pump allowed high-concentration bilirubin plasma to flow in and out through the perfusion tank at a flow rate of 20 mL / min, and an in vitro dynamic perfusion adsorption experiment was performed under simulated normal physiological conditions. Before the experiment, the pipeline was pre-filled with physiological saline for 3 min, and then the pipeline inlet was placed in plasma to flush the pipeline and discard the effluent. The plasma flowed out of the pipeline outlet, and then the pipeline outlet was also placed in plasma to start the in vitro dynamic adsorption experiment. Samples were taken before adsorption and 0.5, 1, 2, 3, and 4 h after adsorption, and the concentrations of TBIL and DBIL before and after adsorption were measured, respectively, and the TBIL adsorption rate was calculated, and the adsorption equilibrium time was observed.

[0140] Adsorption rate = [(C0-C) / C0] × 100%, where C0 is the concentration before adsorption and C is the concentration after adsorption.

[0141] (2) The bilirubin adsorbents commonly used in clinical practice, BRS350 adsorbent, styrene-divinylbenzene polymer prepared in Example 1 and bilirubin adsorbent prepared in Example 1 were selected to conduct in vitro dynamic adsorption comparison experiments on bilirubin plasma with three initial concentrations of 401.4±64.6μmol / L (high concentration group), 189±9.7μmol / L (medium concentration group) and 137.5±17.3μmol / L (low concentration group). The specific experimental steps were the same as above. The perfusion time was 4h. Samples were taken before and after adsorption at 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4h, and the bilirubin concentrations before and after adsorption were measured respectively. The concentration changes of bilirubin by different adsorbents were calculated according to the adsorption rate formula.

[0142] (3) Different concentrations of NaCl (0-0.8 g / L) were added to high bilirubin plasma, and the bilirubin adsorption experiment was carried out according to the steps in (1) to determine the effect of different ion concentrations on the adsorption efficiency.

[0143] (4) Add different concentrations of bovine serum albumin (0-40 g / L) to high bilirubin plasma, perform bilirubin adsorption experiments according to the steps in (1), and determine the effect of different protein concentrations on the adsorption efficiency.

[0144] The results are shown in Table 1 below. The loose porous structure and appropriate pore size of the resin material are conducive to the adsorption of bilirubin by the material.

[0145] Table 1 Effect of pore size of different resin materials on adsorption effect

[0146] ;

[0147] like Fig. 27 As shown, with the increase of adsorption time, the styrene-divinylbenzene polymer prepared in Example 1 and the bilirubin adsorbent prepared in Example 1 have a significant effect on bilirubin (such as Figure 8 The removal efficiency of the two also gradually increased. After 3 hours, the adsorption efficiency of the two tended to be stable, and the difference in efficiency was not large, both reaching more than 60%.

[0148] like Fig.28 As shown, the adsorption efficiency of bilirubin by the styrene-divinylbenzene polymer prepared in Example 1 and the bilirubin adsorbent prepared in Example 1 is not significantly different from that of the clinically commonly used adsorbent BRS350, and there is no significant difference in the adsorption performance of total bilirubin, direct bilirubin and indirect bilirubin.

[0149] like Fig.25 As shown, different concentrations of NaCl have no effect on the bilirubin adsorption efficiency of the styrene-divinylbenzene polymer prepared in Example 1 and the bilirubin adsorbent prepared in Example 1; Fig.26 As shown, a higher concentration of protein will affect the adsorption efficiency of the styrene-divinylbenzene polymer prepared in Example 1, but has almost no effect on the adsorption efficiency of the bilirubin adsorbent prepared in Example 1. This is mainly because the bilirubin adsorbent prepared in Example 1 has better anti-protein adsorption effect.

[0150] The present invention selects Gleditsia sinensis polysaccharide and adopts concentrated sulfuric acid method to carry out sulfate modification on it, so that the sulfated Gleditsia sinensis polysaccharide carries a large number of negatively charged groups. AT III (antiprothrombin III) has high-density positive charges due to the presence of lysine and arginine residues in the molecule. The two can non-specifically bind to induce SPS (sodium polyanethol sulfonate antagonist aminoglycoside) to change the stereo conformation, activate AT III and thus show higher anticoagulant function.

[0151] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A bilirubin adsorbent with anticoagulant effect, characterized in that: The bilirubin adsorbent is prepared by chemically cross-linking sulfated polysaccharide and styrene-divinylbenzene polymer; The mass ratio of the sulfated polysaccharide to the styrene-divinylbenzene polymer in the bilirubin adsorbent is (5-15):(85-95); the sulfated polysaccharide is sulfated saponin polysaccharide; The sulfated Gleditsia sinensis polysaccharide is prepared according to the following steps: Gleditsia sinensis is crushed, and water is used as an extracting liquid to extract Gleditsia sinensis polysaccharide; the Gleditsia sinensis polysaccharide is mixed with a sulfating agent, reacted for 3 to 5 hours, and dialyzed to obtain a precipitate, wherein the precipitate is sulfated Gleditsia sinensis polysaccharide; The ratio of the saponin polysaccharide to the sulfation reagent is 1 g:6 mL; and the reaction is carried out in an ice bath.

2. The method for preparing the bilirubin adsorbent according to claim 1, characterized in that: The following steps are involved: (1) soaking the styrene-divinylbenzene polymer in an acidified solution, acidifying, and vacuum drying to obtain a pretreated styrene-divinylbenzene polymer; (2) mixing the pretreated styrene-divinylbenzene polymer obtained in step (1) with the imine polymer solution and performing an amination reaction to obtain an aminated styrene-divinylbenzene polymer; (3) The aminated styrene-divinylbenzene polymer obtained in step (2) and the sulfated polysaccharide are cross-linked in a constant temperature water bath for 1 to 2 hours under the action of a catalyst to obtain a bilirubin adsorbent.

3. The preparation method according to claim 2, characterized in that: The acidified solution in step (1) is an acid solution with a mass fraction of 25 to 65%; the time of the acidification treatment in step (1) is 2 to 10 minutes; the mass fraction of the imine polymer solution in step (2) is 0.03 to 0.05%, and the imine polymer solution is a polypropylene imine solution; the mixing ratio of the pretreated styrene-divinylbenzene polymer in step (2) and the imine polymer solution is 100 to 150 mL: 150 to 300 mL.

4. The preparation method according to claim 2, characterized in that: The catalyst in step (3) is one or more of KCN, NaSH and CH3BNNa; the amount of the catalyst in step (3) is 0.05-0.15% of the total mass of the reaction system; the temperature of the constant temperature water bath cross-linking in step (3) is 35-45°C.

5. The preparation method according to claim 2, characterized in that: The styrene-divinylbenzene polymer is prepared according to the following steps: Styrene and divinylbenzene are mixed, and an initiator and a porogen are added to prepare an organic phase; the organic phase is homogeneously dispersed with an aqueous solution of hydroxyethyl cellulose to obtain a mixed solution, and the mixed solution is prepared by a suspension polymerization method to obtain a styrene-divinylbenzene polymer.

6. The preparation method according to claim 5, characterized in that: The initiator is azobisisobutyronitrile; the porogen is prepared by mixing toluene, cyclohexanol and n-heptane in a volume ratio of 1:1:0.5; the homogenization time is 2 to 5 minutes, and the homogenization speed is 12000 to 15000 kr / min.

7. Use of the bilirubin adsorbent according to claim 1 or the bilirubin adsorbent obtained by the preparation method according to claim 2 in a blood perfusion system and / or a plasma perfusion system.